{"id":2813,"date":"2020-10-16T14:00:00","date_gmt":"2020-10-16T14:00:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/conference-call-on-interim-report-10\/"},"modified":"2020-10-16T14:00:00","modified_gmt":"2020-10-16T14:00:00","slug":"conference-call-on-interim-report-10","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/conference-call-on-interim-report-10\/","title":{"rendered":"Conference call on Interim Report"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Invitation to attend XVIVO Perfusion\u2019s conference call regarding the presentation of the interim report July \u2013 September 2020. The presentation will be held in English.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>Time: Friday, October 23, 2020 at 2.30 p.m. CET<\/p>\n<p>Information regarding the conference can be found under the following link:<br \/><a href=\"https:\/\/bluejeans.com\/405912591\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/bluejeans.com\/405912591<\/a><\/p>\n<p>Phone numbers to the conference:<br \/>+46.8.5886.8700 (Sweden)<br \/>+46.850.513.580 (Sweden (Stockholm))<br \/>+44.203.608.5256 (UK (London)<br \/>+1.404.458.0105 (United States)<br \/>+47.2160.1825 (Norway (Oslo)<\/p>\n<p>Global Numbers can be found under the link: https:\/\/www.bluejeans.com\/numbers<br \/>Conference name: XVIVO Virtual call, conference ID: 405 912\u00a0591#<br \/>\u00a0<br \/>Participants from XVIVO Perfusion: <br \/>Dag Andersson, CEO <br \/>Christoffer Rosenblad, CFO<br \/>\u00a0<br \/>The telephone conference will be adminsitrated by Ulrik Trattner, Carnegie. To send a question, please email Ulrik.trattner@carnegie.se or use the chat function which you can find in the top right corner of the screen.<br \/>\u00a0<br \/>The press release for XVIVO Perfusion\u2019s interim report July-September 2020 will be released on October 23, 2020 at 7:30 a.m. CET.<br \/>\u00a0<br \/>Before the conference call, slides will be available at the company web page, www.xvivoperfusion.com\/corporate\/.<br \/>\u00a0<br \/>October 16, 2020<br \/>Gothenburg<br \/>XVIVO Perfusion AB (publ)<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts\">\n<p><strong class=\"mfn-heading-1\">For further information please contact:<\/strong><\/p>\n<hr\/>\n<p>Dag Andersson, CEO, +46 76 643 30 31, e-post: <a href=\"mailto:dag.andersson@xvivoperfusion.com\" target=\"_blank\" rel=\"nofollow noopener\">dag.andersson@xvivoperfusion.com<\/a><br \/>Christoffer Rosenblad, CFO, +46 73 519 21 59 e-post: <a href=\"mailto:christoffer.rosenblad@xvivoperfusion.com\" target=\"_blank\" rel=\"nofollow noopener\">christoffer.rosenblad@xvivoperfusion.com<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about\">\n<p><strong class=\"mfn-heading-1\">About Us<\/strong><\/p>\n<hr\/>\n<p>XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden,\u00a0one\u00a0office\u00a0in\u00a0Groningen,\u00a0the\u00a0Netherlands and one office in\u00a0Denver, USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website <a href=\"http:\/\/www.xvivoperfusion.com.\" target=\"_blank\" rel=\"nofollow noopener\">www.xvivoperfusion.com.<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-pdf\">\n<p><strong class=\"mfn-heading-1\">Attachments<\/strong><\/p>\n<hr\/>\n<p><a href=\"https:\/\/storage.mfn.se\/584678c1-9430-4298-bef1-6e712becf3de\/conference-call-on-interim-report.pdf\" class=\"mfn-generated mfn-primary\" target=\"_blank\" rel=\"nofollow noopener\">Conference call on Interim Report<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Invitation to attend XVIVO Perfusion\u2019s conference call regarding the presentation of the interim report July \u2013 September 2020. The presentation&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-2813","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-other"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Conference call on Interim Report - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/conference-call-on-interim-report-10\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Conference call on Interim Report - XVIVO\" \/>\n<meta property=\"og:description\" content=\"Invitation to attend XVIVO Perfusion\u2019s conference call regarding the presentation of the interim report July \u2013 September 2020. The presentation...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/conference-call-on-interim-report-10\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/conference-call-on-interim-report-10\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/conference-call-on-interim-report-10\\\/\",\"name\":\"Conference call on Interim Report - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2020-10-16T14:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/conference-call-on-interim-report-10\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/conference-call-on-interim-report-10\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/conference-call-on-interim-report-10\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Conference call on Interim Report\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Conference call on Interim Report - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/conference-call-on-interim-report-10\/","og_locale":"en_US","og_type":"article","og_title":"Conference call on Interim Report - XVIVO","og_description":"Invitation to attend XVIVO Perfusion\u2019s conference call regarding the presentation of the interim report July \u2013 September 2020. The presentation...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/conference-call-on-interim-report-10\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/conference-call-on-interim-report-10\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/conference-call-on-interim-report-10\/","name":"Conference call on Interim Report - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2020-10-16T14:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/conference-call-on-interim-report-10\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/conference-call-on-interim-report-10\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/conference-call-on-interim-report-10\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Conference call on Interim Report"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2813","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2813"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}